Merck KGaA: Barclays still a buyer

(CercleFinance.com) - Barclays reinstates its "overweight" rating ecommendation on Merck KGaA shares, with a target price of 235 euros, raising its estimates for the group after a third quarter that was deemed "solid", along with an "encouraging" research and development (R&D) update.


"We upgrade our model to reflect higher group margins, consistent performance from Life Sciences and strong delivery from Bavencio & Mavenclad," the broker summarised.

The share is currently up about 1% in a pretty flat market in Frankfurt.


Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.